BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BridgeBio Pharma Inc. (BBIO) Misses Q4 EPS by 7c
February 23, 2023 7:43 AM ESTBridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($0.92), $0.07 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $1.87 million versus the consensus estimate of $5.01 million.
For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.
... More